

Clinical Trials Registry at EDA

S N	Submission date	Study Code (Specified as per the submitted protocol)	Sponsor/ CRO	Study title	Study type: -Interventional -Observational	Study Phase (I, II, III, or IV)	Sites/activation date “At which the clinical trials will be conducted in Egypt”	Status/date: -Approved - Recruiting -Recruitment completion -Completed -Withdrawn -Suspended -Terminated	Conditions / Therapeutic area	Interventions “Used IMPs & its type (Biological, Pharmaceutical , Innovative, Herbal, or medical device)
1-	27\12\2018	M15-991	Sponsor Abbvie	A multi-center, randomized, double-blind, placebo-controlled induction study to assess the efficacy and safety of Risankizumab in subjects with moderately to severely active Crohn’s disease who failed prior biologic treatment	Interventional	III	1-CRC, faculty of medicine, Alexandria university 2-CRC, faculty of medicine, Alexandria university 3-Faculty of medicine, Cairo university 4- MASRI- CRC, Ain Shams University	Approved 26/3/2019 Completed 3/11/2021	moderately to severely active Crohn’s disease who failed prior biologic treatment	(Biological) Risankizumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

							5-National hepatology and tropical medicine institute 6-Faculty of medicine, Zagazig university			
2-	27\12\2018	M16-000	Sponsor Abbvie	A Multicenter, Randomized, Double-Blind, Placebo- Controlled 52- Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease who respond to induction treatment in M16- 006 or M15-991 ;	Interventional	III	Two sites at Faculty of Medicine, CRC, Alexandria University	Approved 26/3/2019 Recruitment completion	Crohn's disease	(Biological) Risankizumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				or completed M15-989						
3-	28\2\2019	M16-066	Sponsor Abbvie	A Multicenter, Randomized, Double-Blind, Placebo- Controlled 52- Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis	Interventional	III	1-Faculty of medicine, CRC, Alexandria University 2-CRC, Alexandria University 3-Air Force Specialized Hospital Research 4- National Liver Institute, Menoufia University	Approved 10/6/2019 Recruitment completion	Ulcerative Colitis	(Biological) Risankizumab
4-	28\2\2019	M16-067	Sponsor Abbvie	Multicenter randomized double-blind placebo-controlled induction study to evaluate the efficacy and safety of Risankizumab	Interventional	III	1- CRC, faculty of medicine, Alexandria University 2-National Liver Institute, Menoufia University	Approved 10/6/2019 Completed: 30/11/2023	Active ulcerative colitis.	(Biological) Risankizumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				in subjects with moderately to severely active ulcerative colitis.			3-Air Force Specialized Hospital 4-Faculty of Medicine, CRC, Alexandria University			
5-	7/5/2019	QGE031	Sponsor: Novartis	A Multicenter, Randomized, double-blind active and placebo-controlled study to investigate the efficacy and safety of Ligelizumab in the treatment of chronic spontaneous urticaria in adolescents and adults in adequately controlled with H1 antihistamines	Interventional	III	1-Faculty of medicine, Alexandria university 2-Faculty of medicine, Ain Shams University	Withdrawn 31/8/2020	Chronic spontaneous Urticaria	(Biological) Ligelizumab

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

6-	18/9/2019	ARTEMI S-DM “LPS1539 6”	SANOVI	A multicenter, multinational, prospective, interventional, single-arm, Phase IV study evaluating the clinical efficacy and safety of 26 weeks of treatment with insulin glargine 300 U/mL (Gla-300) in patients with Type 2 diabetes mellitus uncontrolled on basal insulin	Interventional	IV	1-Faculty of medicine, Alexandria university 2-CRC, Alexandria university 3-GOTHI 4-Faculty of medicine, Menoufia university 5-Faculty of medicine, Ain Shams university	Approved 9/2/2020 Withdrawn	Type 2 diabetes mellitus	(Biological) Insulin glargine “Toujeo”
7-	18/11/2019	STAND	NOVART IS	A phase II, multicenter, randomized, open label, two arm study comparing the effect of crizanlizuma	Interventional	II	1-Abu El Resh Children Hospital	Approved 5/5/2020 Withdrawn 3/8/2021	Sickle cell anemia	(Biological) Crizanlizumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				b+ SOC alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy						
8-	24/3/2020	STEAD FAST	Sponsor: Novartis	A Phase III, multicenter, double-blind study to assess efficacy and safety of two doses of crizanlizumab vs placebo with or without hydroxyurea / hydroxycarbamide therapy, in adolescent and adult sickle cell	Interventional	III	1-Faculty of medicine, Alexandria university 2-Faculty of medicine, Ain Shams university	Approved 20/2/2020 Withdrawn 3/8/2021	Sickle cell anemia	(Biological) Crizanlizumab

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				disease patients with vaso-occlusive crisis						
9-	30/3/2020	WA40404	ROCHE	A Phase III b Multicenter, Randomized, double-blind, Placebo-controlled study to evaluate the efficacy and safety of Ocrelizumab in adults with primary progressive Multiple Sclerosis	Interventional	IIIb	1-Sayed Galal Hospital 2-Faculty of medicine, Alexandria university 3-CRC, MASRI, Ain Shams University	Approved 23/8/2020 Withdrawn 25/8/2021	Primary progressive multiple sclerosis	(Biological) Ocrelizumab
10-	14/9/2020	1368-0025	Boehringer Ingelheim	Open label long term extension study to assess the safety and efficacy of BI655130 treatment in patients with generalized pustular psoriasis	Interventional	I Ib	1-Dermatology department, faculty of medicine, Alexandria university hospital	Approved 18/5/2021 Withdrawn 31/10/2021	Generalized pustular psoriasis	(Biological) Spesolimab

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

11-	21/9/2020	05-Gam-COVID-Vac-2020	Sponsor: Russian Direct Investmen t Fund (RDIF)	A Phase III, randomized, double blind, placebo-controlled trial to evaluate immunogenicity and safety of the Gam-COVID-Vac combined vector vaccine in prophylactic treatment for SARS-COV-2 infection in Egypt	Interventional	III	1-National liver institute, Menoufia university 2-CRC, faculty of medicine, Alexandria university 3- CRC, MASRI, Ain Shams University	Withdrawn 12/6/2022	COVID-19 prophylaxis	(Biological) Russian Gam-COVID-Vac Combine vector vaccine
12-	22/9/2020	CNBG20 20003SQ	China National Biotec Group company limited Wuhan institute of biological	Multicenter, Randomized, Double blind, parallel placebo controlled, Phase III clinical trial to evaluate the protective efficacy, safety and immunogenicity of Inactivated SARS-COV-2 Vaccines	Interventional	III	1-Vacsera Health care facility 2-Ktameya medical center	Approved 28/3/2022 Completed 31/7/2022	COVID-19 Prophylaxis	(Biological) Inactivated SARS-COV-1 Vaccine

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

			products Co. Ltd Beijin institute of biological products Co.Ltd	in healthy population aged 18 years old and above						
13-	13/4/2021	D910DC0 0001 (Emerald- 2)	Sponsor: AstraZene ca CRO: IQVIA	A phase 3 randomized double blind placebo controlled multicentre study of durvalumab monotherapy or in combination with bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma who are at high risk of recurrence after curative hepatic	Interventional	III	1-CRC, Faculty of medicine, Alexandria University hospital 2-National Liver Institute- Menoufia University 3-National Hepatology & Tropical Medicine Research Institute	Approved 12/12/2021 Recruitment completion	Hepatocellula r carcinoma patients at high risk of recurrence after curative hepatic resection or ablation	(Biological) Durvalumab\ Bevacizumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				resection or ablation			4-Air Force specialized Hospital 5-Faculty of medicine, Assuit University			
14-	19/5/2021	01-Sputnik-Light-2021	Sponsor: Human vaccine LLC (Global), Russian ministry of healthcare – Gamalya (Local) CRO: PDC	A phase III, randomized, double-blind, placebo-controlled international multi-site clinical trial in parallel assignment to evaluate efficacy, immunogenicity and safety of the Sputnik Light vector vaccine in adults in the SARS-Cov-2 infection prophylactic treatment	Interventional	III	1- National hepatology and tropical medicine center 2-Katemeya medical center	Approved 24/8/2021 Completion of study visit 31/8/2022	COVID-19 Prophylaxis	(Biological) Sputnik Light vector vaccine
15-	25/5/2021	KATE-3	Sponsor: ROCHE	A randomized, multi-center,	Interventional	III	1-Faculty of medicine, Kasr	Approved 5/12/2021	HER2-positive and	(Biological)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				double blind, placebo-controlled phase III study of the efficacy and safety of Trastuzumab Emtansine in combination with Atezolizumab or placebo in Pts with HER2-positive and PD-L1- positive locally advanced or metastatic breast cancer who have received prior Trastuzumab + Atezolizumab and Taxane- based therapy			Al-Ainy hospital 2-Shefaa Al- Orman hospital 3-Baheya Hospital	Withdrawn 19/12/2022	PD-L1- positive locally advanced or metastatic breast cancer	Trastuzumab Emtansine/ Atezolizumab
16-	27/5/2021	CAIN457 P12301	Sponsor: Novartis	A randomized, double blind, placebo- controlled, parallel group, phase III multi-center study	Interventional	III	1-CRC, Faculty of medicine, Alexandrian university	Withdrawn 3/11/2021	Active ankylosing spondylitis	(Biological) Secukinumab

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				of intravenous Secukinumab to compare efficacy at 16 weeks with placebo and to assess safety and tolerability up to 52 weeks in subjects with active ankylosis spondylitis of non-radiographic axial spondylo arthritis						
17-	5/8/2021	TG2101V01	Sponsor: Livzon mabpharm Inc.	A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein	Interventional	III	1-National Hepatology and Tropical Medicine Research Institute (NHTMRI)	Withdrawn 16/1/2022	COVID-19 Prophylaxis	(Biological) Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Vaccine (V-01) in Adults Aged 18 Years and Older",						
18-	18/8/2021	MO42541	Sponsor: ROCHE	A phase III, open label, randomized study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or sorafenib alone in hepatocellular carcinoma previously treated with Atezolizumab and Bevacizumab	Interventional	III	Air force specialized hospital	Approved 2/2/2022 Recruitment completion	Hepatocellular carcinoma	(Biological) Atezolizumab/ Lenvatinib/ Sorafenib
19-	2/9/2021	COVID_VACC_1	Sponsor: National research center CRO: CLINMA X	A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Inactivated SARS-CoV-2 Vaccine Against COVID-19 in Healthy Adults	Interventional	I	National research center	Approved 9/11/2021 Suspended 9/12/2021	Covid-19 Prophylaxis	(Biological) Inactivated SARS-CoV-2 Vaccine

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

20-	17/1/2022	SPHINX-EGYPT SPHINX2 2122020	Sponsor: - EVA PHARMA - VSVRI - supreme council of university hospitals - Ministry of higher education and scientific research CRO: Dataclin	Safety and Immunogenicity Study of EgyVax Vaccine Candidate for Prophylaxis of SARS-CoV-2 Infection (COVID-19)	Interventional	I	Al-Manial specialized university Hospital, Cairo university hospitals	Approved 3/2/2022 Database lock 26/9/2023	Covid-19 Prophylaxis	(Biological) EgyVax
21-	4/11/2021	GBT2104-131	Sponsor: Global blood therapeutics Inc. \ Pfizer CRO: MCT	A randomized double blinded placebo controlled multicentre study to access the safety and efficacy of Inclacumab in participants with sickle cell disease experiencing	Interventional	III	1-Faculty of medicine, Mansoura University 2-Faculty of medicine, Zagazig University 3-MASRI-CRC, Faculty	Approved 14/6/2022 Recruitment completion	sickle cell disease patients with Vaso-occlusive crisis	(Biological) Inclacumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Vaso-occlusive crisis			of medicine, Ain Shams University hospital 4-CRC, Alexandria University 5- Pediatric hematology department, Alexandria University 6. CRC, faculty of medicine, Cairo University, Abo El-Resh Hospital 7- CRC, Cairo University 8- Hematology department, Cairo University hospital			
22-	4/1/2022	GBT2104 -132		A Randomized, Double-blind,	Interventional	III	1. Faculty of medicine,	Approved 14/6/2022	Sickle cell disease	(Biological)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			Global blood therapeu tics Inc.\ Pfizer CRO: MCT	Placebo- controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re- admission in Participants with Sickle Cell Disease and Recurrent Vaso- occlusive Crises (GBT-132)			Mansoura University 2. Faculty of medicine, Zagazig University 3. MASRI, CRC, Ain Shams University 4. Hematology unit, Internal medical department, CRC, faculty of medicine Alexandria University hospital 5- Hematology department, Alexandria University hospital 6. Cairo University,	Withdrawn 29/6/2023	patients with Vaso- occlusive crisis	Inclacumab
--	--	--	--	---	--	--	--	------------------------	---	------------

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

							Abo El-Resh Hospital 7- CRC, Cairo University 8- Cairo University, Hematology department.			
23-	28/11/2021	GBT2104-133	Global blood therapeutics Inc.\ Pfizer CRO: MCT	An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sick Cell Disease Who Have Participated in an Inclacumab Clinical Trial	Interventional	III	1. Faculty of medicine, Mansoura University 2. Faculty of medicine, Zagazig University 3. MASRI, CRC, Ain Shams University 4. Hematology unit, Internal medical department, CRC, faculty of medicine Alexandria	Approved 14/6/2022 Withdrawn 17/12/2023	sickle cell disease	(Biological) Inclacumab/ Placebo

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

							University hospital 5- Hematology department, Alexandria University hospital 6. Cairo University, Abo El-Resh Hospital 7- CRC, Cairo University 8- Cairo University, Hematology department.			
24-	8\6\2022	Consonance- MN39159	Sponsor: F.HOFFMANN-LA ROCHE LTD CRO: Roche Egypt LLC &	An open-label, single-arm 4-year study to evaluate effectiveness and safety of ocrelizumab treatment in patients with progressive multiple sclerosis	Interventional	III	1-CRC, Faculty of Medicine, Alexandria university, CRC 2-MASRI-CRC,faculty of medicine, Ain Shams	Approved 20/9/2022 Recruitment completion	Progressive multiple sclerosis	(Biological) Ocrelizumab

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			IQVIA (for monitorin g activities only)				university hospital			
25-	9\2\2022	20200404 (IMBCA M	Sponsor: Institute of Medical Biology Chinese Academy of Medical Sciences CRO: PDC	A randomized double-blinded placebo-controlled Phase III clinical trial of SARS- COV-2 vaccine inactivated (Vero cell) in adult aged 18 years and above	Interventional	III	1-Katameya Medical Center 2- National Hepatology and tropical medicine institute	Withdrawn 24/2/2022	Covid-19 Prophylaxis	(Biological) Inactivated SARS-COV-2 vaccine
26-	10/5/2022	TRISTAR DS- 0135- 0347	Sponsor: Boehringer Ingelheim CRO: MCT	The TRISTARDS trial -Thrombolysis is Therapy for ARDS A Phase IIb/III operationally seamless, open- label, randomized, sequential,	Interventional	IIb/III	1.National Hepatology and Tropical Medicine Research Institute 2.Abbasia Fever Hospital	Withdrawn 20/7/2022	Respiratory distress syndrome (ARDS) triggered by COVID-19	(Biological) Alteplase

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				parallel-group adaptive study to evaluate the efficacy and safety of daily intravenous alteplase treatment given up to 5 days on top of standard of care (SOC) compared with SOC alone, in patients with acute respiratory distress syndrome (ARDS) triggered by COVID-19.			3.Imbaba Fever Hospital			
27-	14/8/2022	CAIN457 A2310	Sponsor: Novartis CRO: MCT	A randomized, double-blind, placebo- and active controlled multicenter trial to demonstrate efficacy of subcutaneous Secukinumab compared to	Interventional	III	1-CRC, Faculty of Medicine, Alexandria university hospital 2-Dermatology department, faculty of Medicine, Ain Shams	Approved 4/12/2022 Early terminated by sponsor 31/3/2023	Treatments of severe chronic plaque psoriasis	(Biological) Secukinumab

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				placebo and etanercept (in a single blinded arm) after twelve weeks of treatment, and to assess the safety, tolerability, and long-term efficacy in subjects from 6 to less than 18 years of age with severe chronic plaque psoriasis			University hospital			
28-	8/11/2022	SCTV01E-MRCT-1	Sponsor: Sinocelltech CRO: PDC	A randomized double blind positive controlled phase III clinical trial to evaluate the efficacy and safety of SCTV01E (a covid-19alpha/beta/delta/ omicron variants s-trimmer vaccine) in population	Interventional	III	1-Katemya Medical Center 2-Egyptian Liver research institute and hospital	Withdrawn 14/1/2023	COVID-19 prophylaxis	(Biological) SCTV 01E (a covid-19 alpha/beta/delta/ omicron variants s-trimmer vaccine) (Biological)

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				previously unvaccinated with COVID-19 vaccine and aged ≥18						
29-	6/6/2023	FUZION CNT019 59CRD	Sponsor: Janssen CRO: MCT	A Phase 3, Randomized, Placebo- controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn's Disease "FUZION CD"	Interventional	III	1.National Hepatology Tropical Medicine Research Institute 2.CRC, faculty of medicine Alexandria university hospital, (two sites) 3. Department of internal medicine, El Kasr Al Aini, Cairo University 4. MASRI CRC, faculty of medicine, Ain Shams	Approved 13/8/2023 Recruiting	Fistulizing perianal Crohn's disease	Guselkumab (Biological)

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

							University Hospital			
30-	MP- ADA1-01	14/5/2023	Sponsor: Minapharm CRO: CRS Clinical Research Services Berlin GmbH	A Phase I, randomized, double-blind, 2-arm, parallel group trial to compare pharmacokinetics of Adessia with EU-authorized Humira in healthy male and female participants”	Interventional	I	-CRS clinical research services, Berlin GmbH -CRS clinical research services, Mannheim GmbH	Approved 10/8/2023 Completed	Inflammatory disease (Biosimilar to Humira)	Adessia (Biological)
31-	4/5/2023	MOM-M281-006	Sponsor: Janssen CRO: MCT	Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study with a Long-term Open-label Extension”	Interventional	II/III	-National Cancer Institute, Cairo university -Oncology center, Mansoura University Hospital -Department of internal medicine, Al Kasr al Eini, Cairo university	Approved 19/7/2023 Recruiting	Warm Autoimmune Hemolytic Anemia	M281 (Biological)

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

							-Naser institute hospital for research and treatment -CRC, faculty of medicine, Alexandria university Hospital -CRC, faculty of medicine, Ain shams university Hospital			
32-	9\10/2023 shift to amendment submission 26\12\2023	EMERAL D-3) D910VC0 0001	Sponsor: AstraZene ca CRO: IQIVIA	A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization	Interventional	III	- Air Force specialized hospital - Oncology department, Faculty of medicine, Alex University - Egyptian liver Hospital - National Hepatology and Tropical Medicine	Approved 8/2/2024 Recruiting	Locoregional Hepatocellular Carcinoma	(Biological) Durvalumab / Tremelimumab/ Lenvatinib /TACE

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				(TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3)			Research Institute (NHTMRI) - Shifa El orman Hospital			
33-	not submitted officially	CERE-CAP	investigat or-initiated	Efficacy of Cerebrolysin as an adjuvant therapy following mechanical thrombectomy in patients with large vessels occlusion stroke	Interventional	III	Neurology and psychiatry department, Ain Shams University Hospital	Terminated (by EDA) (15/1/2024)	occlusion stroke	(Biological) CEREBROLY SIN solution for IM or IV injection/ concentrate for solution for I.V. infusion
34-	14/12/2023	BCD-178	Sponsor: JSC BIOCAD CRO: Dataclin	A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer	Interventional	III	-Faculty of Medicine, Aleandria UNIVERSITY -Faculty of Medicine , Cairo University	Approved: 22/4/2024	Her-2 positive breast cancer	Biological BCD-178

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

35-	8/1/2024	SerpinPc 102	Sponsor: Apcintex CRO: MCT	A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects with Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (AP-0102)	Interventional	IIb	Ain Shams University Medical Research Institute (MASRI)	Conditional Approved 13/6/2024 Final Approval 31/10/2024 Withdrawn: 16/01/2025	Hemophilia A or Moderately Severe to Severe Hemophilia B	Biological SerpinPC 102
36-	8/1/2024	SerpinPC 103	Sponsor: Apcintex CRO: MCT	A Global, Open-label Study to Investigate the Efficacy and Safety of SerpinPC in Subjects with Hemophilia B with Inhibitors (AP-0103)	Interventional	IIb	Ain Shams University Medical Research Institute (MASRI)	Conditional Approved 13/6/2024 Final Approval 31/10/2024 Withdrawn: 16/01/2025	Hemophilia B with Inhibitors	Biological Serpin PC 103
37-	8/2/2024	D9185C00 001'TILI A'	Sponsor: AstraZenca	A Phase III, Multicenter, Randomized,	Interventional	III	1-Air Force specialized Hospital	Approved: 4/8/2024	Patients hospitalized	Biological

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			CRO: IQVIA	Double-bind, Parallel-group, Placebo- Controlled study to evaluate the efficacy and safety of Tozoralimab (MEDI3506) in patients hospitalized for viral lung infection requiring supplemental oxygen			2-Ain Shams University Medical research Institute (MASRI-CRC) 3-CRC, Alexandria University Hospital		for viral lung infection	Tozoralimab
38-	17/12/2020	CEGA23 0B2404	Sponsor: Novartis CRO: MCT	A Phase IV Multicenter Open Label Study to Determine the Safety, Tolerability and Clinical Outcomes Following Oral Administration of Egaten (Triclabandazole) in Patients 6 Years of Age or Older	Interventional	IV	1-Cairo University, Al Mounira Children Hospital, Pediatric Hepatology Unit. 2-Alexandria University, Faculty of Medicine, Clinical	Approved 12/4/2021 Recruiting	Fascioliasis	(Pharmaceutical) Triclabandazole (Egaten)

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				with Fascioliasis (Egaten)			Research Center.			
39-	22/12/2020	CLEE011 A3201C RIGHT Choice	Sponsor: Novartis CRO: MCT	A Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate with Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients with Hormone Receptor- Positive/HER2- Negative Inoperable Locally Advanced or Metastatic Breast Cancer - RIGHT Choice Study	Interventional	II	1-Ain Shams University, Faculty of Medicine, Clinical Research Center, (MASRI – CRC) 2-Baheya Hospital Research Center 3-Cairo University, NEMROCK 4-Nasser Institute Cancer Center	Approved 14/10/2021 Completed 8/1/2023	HER-2 Negative Breast Cancer	(Pharmaceutical) Ribociclib Plus Goserelin / Physician Choice Chemotherapy
40-	24/10/2021	M14-430	Sponsor: Abbvie CRO: NA	A Multicenter, Randomized, Double-Blind,	Interventional	III	1-Air Force Specialized Hospital	Approved 7/7/2022	Chron's Disease	(Pharmaceutical)

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Placebo- Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease Who Completed the Studies M14- 431 or M14-433			2-National Liver Institute Menoufiya University 3-Alexandria University, Faculty of Medicine, Clinical Research Center. 4-Ain Shams University, Faculty of Medicine, Clinical Research Center (MASRI-CRC).	Recruitment Completion		Upadacitinib/ matching placebo
41-	26/10/2021	BO40336 ALINA	Sponsor: Roche CRO: NA	A Phase III, Open- Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in	Interventional	III	1- Cairo University, Kasr Al Eini, Center of Radiation Oncology and Nuclear Medicine.	Approved 16/3/2022 Recruitment Completion	Lung Cancer	(Pharmaceutical) Alectinib / Platinum based Chemotherapy

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Patients with Completely Resected Stage Ib (Tumors $\geq$ 4 Cm) To Stage IIIa Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer						
42-	12/12/2021	Cl_Tr_17 122019 MIRACL E-ALA	Sponsor: EVA Pharma CRO: MARC	A Multicenter, Interventional, Two-Arm, Parallel-Group, Randomized, Double-Blinded, Placebo-Controlled, Phase IV Trial to Evaluate the Efficacy of Alpha-Lipoic Acid in the Treatment of Patients with Symptomatic Diabetic	Interventional	IV	1- Alexandria University Hospital, Diabetes, Metabolism, and Lipidology Unit, Department of Internal Medicine. 2- Ain Shams University Hospital 3- Menoufiya University Hospital 4- Mansoura University,	Approved 12/10/2022 Completed 11/12/2024	Treatment of Symptomatic Diabetic Polyneuropathy	(Pharmaceutical) Alpha-Lipoic Acid (Thiotacid)/ matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Polyneuropathy in Egypt			Intrinsic Specialized Hospital. 5- Beni-Suef University Hospital, Diabetes and Endocrinology Unit.			
43-	12/12/2021	MK4482-013 MOVE-Ahead	Sponsor: MSD CRO: NA	A Phase 3 Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory Confirmed SARS-COV 2 Infection with Symptoms) in Adults.	Interventional	III	1-Ain Shams University Clinical Research Center (MASRI-CRC). 2-Air Force Specialized Hospital. 3-National Hepatology and Tropical Medicine Research Institute. 4-Imbaba Fever Hospital.	Approved 18/1/2022 Completed 16/11/2022	Prophylaxis of COVID-19	(Pharmaceutical) Molnupiravir/ matching placebo

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

							5-National Center for Allergies and Chest Imbaba			
44-	30/3/2022	GBT440-032	Sponsor: GBT (Subsidiary of Pfizer) CRO: CTI	A Phase 3, Randomized, Double-Blind, Placebo- Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease (HOPE Kids 2)	Interventional	III	1-Ain Shams University Clinical Research Center (MASRI- CRC). 2-Alexandria University Clinical Research Center. 3- Al Mounira Children Hospital, Cairo University, 4-Zagazig University Hospital, Department of Pediatrics.	Approved 31/7/2022 IMP Dosing Pause 02/05/2024 Early Termination by the sponsor 29/09/2024	Sickle Cell Disease	(Pharmaceutical) Voxelotor/ matching placebo
45-	18/4/2022	GBT440-034	Sponsor: GBT	An Open Label Extension Study of	Interventional	III	1-Cairo University,	Approved	Sickle Cell Disease	(Pharmaceutical)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			(Subsidiary of Pfizer) CRO: IQVIA	GBT440 Administered Orally to Patients with Sickle Cell Disease who Have Participated in GBT440 Clinical Trials			Abu El Rich Hospital. 2-Ain Shams University Clinical Research Center (MASRI-CRC) 3-Alexandria University Clinical Research Center 4-Zagazig University Hospital, Department of Pediatrics.	2/8/2022 Early Termination by the sponsor 30/09/2024		Voxelotor
46-	17/5/2022	F901318/ 0032	Sponsor: F2G CRO: IQVIA	Open Label Single Arm Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Seedosporium	Interventional	IIb	1-Mansoura University Oncology center 2-Alexandria University, Clinical Research Center	Terminated (By Sponsor) 24/7/2022	Invasive Fungal Infection	(Pharmaceutical) Olorofim

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Spp., Aspengillus Spp., & other Resistant Fungi in Patients Lacking Suitable Alternative			3-Nasser Institute 4-Ain Shams University Clinical Research Center, (MASRI – CRC) 5-Air Force specialized Hospital 6-National Cancer Institute 7-Cairo University Kasr Al-Eini, Hospital			
47-	12/6/2022	CLSYN.1 702 (OASIS- 9)	Sponsor: Hamilton Health Science CRO: Clinmax	A 2x2 Factorial Randomized Controlled Trial of CoLchicine and spironolactonE in Patients With myocARDial infarction/SYNER GY Stent Registry	Interventional	III/IV	1-Mansoura University Hospital 2-Suez Canal University Hospital 3-Fayoum General Hospital	Approved 24/7/2022 Completed 01/08/2024	STEMI/Non- STEMI Myocardial Infarction	(Pharmaceutical) Colchicine, Spironolactone/ matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				– Organization to Assess Strategies for Ischemic Syndromes 9			4-Tamia Central Hospital 5-El Kharga Specialized Hospital 6-National Heart Institute			
48-	15/6/2022	20140106	Sponsor: Onyx Pharmaceuticals (Subsidiary of Amgen) CRO: IQVIA	Phase 1b/2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia	Interventional	Ib/II	1-Children's Cancer Hospital 57357	Approved 23/8/2022 Withdrawn 19/6/2023	Relapsed or Refractory Acute Lymphoblastic Leukemia	(Pharmaceutical) Carfilzomib
49-	18/7/2022	AG348-C-020	Sponsor: Agios CRO: MCT	A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of	Interventional	II/III	1-Alexandria University Clinical Research Center 2-Zagazig University Hospital	Approved 27/9/2022 Withdrawn 21/8/2023	Sickle Cell Disease	(Pharmaceutical) Mitapivat / matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Mitapivat in Subjects with Sickle Cell Disease			3-Cairo University Hospital 4-Mansoura University Hospital 5-Ain Shams University Clinical Research Center (MASRI-CRC)			
50-	26/7/2022	F901318/ 0041	Sponsor: F2G CRO: IQVIA	A Phase III, Adjudicator- Blinded, Randomised Study to Evaluate the Efficacy and Safety of Treatment with Olorofim Versus Treatment with Ambisome® Followed by Standard of Care (SOC) in Patients with Invasive	Interventional	III	1-Mansoura University Oncology Center 2-Alexandria University Clinical Research Center 3-Air Force specialized Hospital 4-Ain Shams University, Clinical	Approved 11/10/2022	Invasive Fungal Disease caused by Aspergillus species	(Pharmaceutical) Olorofim / Ambisome

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Fungal Disease (IFD) Caused by Aspergillus Species			Research Center (MASRI-CRC) 5-Zagazig University Hospital 6-National Cancer Institute 7-Cairo University Kasr Al Eini Hospital 8-Nasser Institute for Research and Treatment			
51-	27/7/2022	APD334-202	Sponsor: Arena Pharmaceuticals (Subsidiary of Pfizer)	A Multicenter Randomized Double Blinded Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for	Interventional	III	1-Alexandria University Clinical Research Center 2-Air Force Specialized Hospital 3-National Liver Institute	Approved 23/8/2022 Recruitment Completion	Moderately to Severe Active Crohn's Disease	(Pharmaceutical) Etrasimod / matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Moderately to Severe Active Crohn's Disease (Etrasimod)			4-National Hepatology and Tropical Medicine Research Institute (NHTMRI) 4-Cairo University Kasr Al-Eini Hospital 5-Egyptian Liver Research Institute and Hospital 6-Ain Shams University Hospital 7-Theodor Bilharz Research Institute			
52-	7/8/2022	EFC1721 5 LEAP-2-MONO	Sponsor: Sanofi CRO: NA	A Phase 3, Multicenter, Multinational Randomized Double-Blind	Interventional	III	1-Alexandria University Hospital Clinical	Approved 24/10/2022	Gaucher Disease Type 3 (GD3)	(Pharmaceutical) Venglustat/ Cerezyme

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Double-Dummy, Active Comparator Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients with Gaucher Disease Type 3 (GD3) who Have Reached Therapeutic Goals with Enzyme Replacement Therapy			Research Center			
53-	15/8/2022	AG348-C-017	Sponsor: Agios CRO: MCT	A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in	Interventional	III	1-Cairo University Hospital 2-Ain Shams University Clinical Research Center MASRI-CRC	Approved 2/11/2022 Withdrawn 26/6/2023	Non-Transfusion-Dependent Alpha or Beta Thalassemia	(Pharmaceutical) Mitapivat / matching placebo

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Subjects with Non-Transfusion-Dependent Alpha- or Beta- Thalassemia (ENERGIZE)						
54-	15/8/2022	AG348-C-018	Sponsor: Agios CRO: MCT	A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects with Transfusion-Dependent Alpha- or Beta- Thalassemia (ENERGIZE-T)	Interventional	III	1-Cairo University Hospital 2-Ain Shams University Clinical Research Center MASRI-CRC	Approved 2/11/2022 Withdrawn 26/6/2023	Transfusion-Dependent Alpha or Beta Thalassemia	(Pharmaceutical) Mitapivat / matching placebo
55-	29/8/2022	4202-HEM-301	Sponsor: Forma Therapeutics	An Adaptive, Randomized, Placebo-Controlled, Double-blind,	Interventional	III	1- Alexandria University Clinical Research Center	Approved 11/12/2022 Recruiting	Sickle Cell Disease	(Pharmaceutical) Etavopivat / matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			CRO: MCT	Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease			2-Zagazig University Hospital 3-Cairo University Hospital 4-Ain Shams University Clinical Research Center (MASRI-CRC)			
56-	29/9/2022	GO42784 LIDERA	Sponsor: Roche CRO: MCT	A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen	Interventional	III	1-Alexandria University Hospital 2-Medical Research Institute, Alexandria University 3-Mansoura University Hospital 4-Cairo University Kasr Al- Ainy Hospital	Approved 4/12/2022 Recruitment Completion	Estrogen Receptor -Positive , Her2- Negative Early Breast Cancer	(Pharmaceutical) Giredestrant / Physician Choice of Adjuvant Endocrine Monotherapy

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Receptor-Positive, Her2-Negative Early Breast Cancer			5-Ain Shams University Demerdash Hospital 6- Dar El Salam Cancer Hospital 7- Sohag Oncology Center			
57-	16/11/2022	(ACTIV- 2D/A540 7)	Sponsor: Shionogi CRO: IQVIA	A Phase 3, Multicenter, Randomized, Double-Blind, 24- Week Study of the Clinical and Antiviral Effect of S-217622 Compared with Placebo in Non- Hospitalized Participants with COVID-19	Interventional	III	1-National Hepatology and Tropical Medicine Research Institute 2-Ain Shams University Clinical Research Center (MASRI-CRC) 3-Alexandria University Clinical Research Center, 4-Air	Approved 31/1/2023 Withdrawn 26/9/2023	Covid-19 treatment	(Pharmaceutical) S-217622 / matching placebo

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

							Force Specialized Hospital 5-National Institute for Chest Allergy and Diseases 6-Imbaba Fever Hospital			
58-	28/11/2022	RBSC216 1	Sponsor: Salix pharmace uticals CRO: IQVIA	A Phase 2a Randomized, Double-Blind, Placebo- Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamic s of Rifaximin Novel Formulations in Patients with Sickle Cell Disease	Interventional	Ila	1-Cairo University Abu El Rich Hospital. 2-Ain Shams University Clinical Research Center (MASRI-CRC) 3-Zagazig University Hospital 4-Cairo University Hospital 5-Alexandria University	Approved 5/2/2023 Withdrawn 6/11/2023	Sickle Cell Disease	(Pharmaceutical) Rifaximin / matching placebo

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

							Clinical Research Center			
59-	22/1/2023	AT/03A-017	Sponsor: Atea Pharmace uti-cals CRO: Avicemer	A Phase 3 Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19	Interventional	III	1- National Hepatology and Tropical Medicine Research Institute	Approved: 15/10/2023 Withdrawn 7/4/2024	COVID-19	(Pharmaceutical) Bemnifosbuvir/ matching Placebo
60-	13/2/2023	ENRICH-AF	Sponsor: Hamilton Health Science CRO: Clinmax	Edoxaban for Intracranial Haemorrhage Survivors with Atrial Fibrillation (ENRICH- AF) Edoxaban 60/30mg once daily	Interventional	IV	1-Ain Shams University Clinical Research Center (MASRI-CRC) 2-Zagazig University Hospital 3-Fayoum General Hospital	Approved 10/5/2023 Recruiting	Atrial Fibrillation in patients with previous Intracranial Haemorrhage	(Pharmaceutical) Edoxaban

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

							4-Tanta University Hospital 5-Mansoura University Hospital 6-Ain Shams Specialized Hospital 7-Alexandria University Clinical Research Center 8-Assuit University Hospital			
61-	13/2/2023	GBT440-038	Sponsor: GBT (Subsidiary of Pfizer)	An Open-Label Extension Study of Voxelotor Administered Orally to Paediatric Participants with Sickle Cell Disease Who Have Participated in	Interventional	III	1-Alexandria University Clinical Research Center 2- Zagazig University Hospital 3-Cairo University,	Approved 30/3/2023 IMP Dosing Pause 02/05/2024 Early Terminated by	Sickle Cell Disease	(Pharmaceutical) Voxelotor

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Voxelotor Clinical Trials			Abu El Rich Hospital. 4- Ain Shams University, Faculty of Medicine CRC (MASRI).	the Sponsor 26/9/2024		
62-	1/3/2023	GN41851 FENHAN CE	Sponsor: Roche CRO: NA	A Phase III Multicentre, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide In Adult Patients with Relapsing Multiple Sclerosis.	Interventional	III	1-Alexandria University-Clinical Research Center	Approved 26/4/2023 Withdrawn 11/1/2024	Relapsing multiple sclerosis	(Pharmaceutical) Fenebrutinib/ Teriflunomide/ matching placebo
63-	6/3/2023	1305-0023 (FIBRONE ER –ILD	Sponsor: Boehringer Ingelheim	A Double Blind, Randomized, Placebo-Controlled Trial	Interventional	III	1-Ain Shams University Clinical Research	Approved 1/6/2023	Progressive Fibrosing Interstitial	(Pharmaceutical)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			CRO: IQVIA	Evaluating the Efficacy and Safety of BI 1015550 Over At Least 52 Weeks in Patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)			Center (MASRI-CRC) 2- Alexandria University Clinical Research Center 3- Air Force Specialized Hospital 4- Cairo University, Kasr Al Aini Hospital	Withdrawn 17/1/2024	lung diseases (PF-ILDs)	BI 1015550 / matching placebo
64-	6/3/2023	1305-0014 (FIBRON EER – IPF)	Sponsor: Boehringer r Ingelheim CRO: IQVIA	A Double Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over At Least 52 Weeks in Patients with Idiopathic Pulmonary Fibrosis (IPF)	Interventional	III	1- Ain Shams University Clinical Research Center (MASRI-CRC) 2- Alexandria University Clinical Research Center	Approved 1/6/2023 Withdrawn 08/01/2024	Idiopathic Pulmonary Fibrosis (IPF)	(Pharmaceutical) BI 1015550 / matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

							3- Air Force Specialized Hospital 4- Cairo University, Kasr Al Ainy Hospital			
65-	16/3/2023	4202- HEM-201	Sponsor: Forma Therapeut ics CRO: MCT	A Phase 2 Open- Label Study to Evaluate Safety and Clinical Activity of FT- 4202 in Patients with Thalassemia or Sickle Cell Disease	Interventional	II	1- Cairo University, Abu El-Rich Children Hospital. 2-Cairo University, Kasr Al Eini Hospital.	Approved 1/6/2023 Recruiting	Thalassemia or Sickle Cell Disease	(Pharmaceutical) Etavopivat
66-	15/5/2023	EFC16035 (PERSEUS)	Sponsor: Sanofi CRO: NA	A Phase 3, Randomized, Double-Blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants with Primary	Interventional	III	Alexandria University Clinical Research Center	Approved 10/8/2023 Withdrawn 15/4/2024	Primary Progressive Multiple Sclerosis	(Pharmaceutical) Tolebrutinib/ Matching Placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Progressive Multiple Sclerosis						
67-	14/3/2024	WO43571 HereDER A	Sponsor: Roche CRO: NA	A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination with Phesgo Versus Phesgo After Induction Therapy with Phesgo+ Taxane in Patients with Previously Untreated Her2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer	Interventional	III	1- Sohag Oncology Center 2- Dar El Salam Cancer Hospital 3- National Cancer Institute	Approved 8/4/2024 Recruiting	Previously Untreated Her2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer	Pharmaceutical Giredestrant
68-	22/4/2024	1517-CL-1003	Sponsor: Astellas Pharma Global	A Phase 3, Open-label, Uncontrolled Study to Evaluate	Interventional	III	1- Cairo University Children's Hospital	Approved 10/7/2024 Withdrawn	Anemia in Pediatric Patients with Chronic	Pharmaceutical Roxadustat

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			Developm ent CRO: MCT	the Activity, Safety, Pharmacokinetics and Pharmacodynamic s of Roxadustat for the Treatment of Anemia in Pediatric Participants with Chronic Kidney Disease 1517-CL-1003			1- Ain Shams University Hospital 3- Alexandria University Hospital	26/9/2024	Kidney Disease	
69-	5/6/2024	M23-698	Sponsor: Abbvie CRO: NA	A Phase 3, Randomized, Placebo- Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to	Interventional	III	1- Ain Shams University CRC (MASRI) 2- Air Force Specialized Hospital 3- Alexandria University CRC	Approved 7/8/2024	Moderate to Severe Hidradenitis Suppurativa	Pharmaceutical Upadacitinib

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Severe Hidradenitis Suppurativa Who Have Failed Anti- TNF Therapy M23-698						
70-	24/7/2022	MD-004	Sponsor: Ezz Medical Industries CRO:Data clin	Open labelled non randomized self- controlled study to evaluate the safety and performance of Ezvent in hospitalized mechanically ventilated patients	Interventional	III	1-Kasr Al-Aini university Hospital	Approved 28/8/2022 Suspended 1-1-2024 Resuming (ongoing) 13/1/2024	Hospitalized mechanically ventilated patients	Medical device (Ezvent)
71-	15/5/2022	COAV10 1B12301	Sponsor: Novartis CRO: MCT	A randomized sham controlled double –blind study to evaluate the efficacy and safety of intrathecal (IT) QAV101 in patients with later onset type 2 spinal muscular atrophy	Interventional	III	1-Department of Neurology, Ain Shams University Specialized Hospital.	Approved 2-8-2022 Early terminated (by sponsor) 18-12-2023	type 2 spinal muscular atrophy (SMA)	Innovative QAV101 (Zolgensma) (Onasemnogene abeparvovec)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				(SMA) who are ≥ 2 to <18 years of age, treatment naïve sitting and never ambulatory						
72-	6/6/2023	Urso-003	Sponsor: Minapharm	Multi-Center, randomized, control, phase IV trial to compare the efficacy & safety of Ursoplus® capsules (UDCA 250mg & Silymarin 140mg) versus UDCA alone versus Placebo among Compensated Chronic Liver Disease Patients	Interventional	IV	Clinical Research Center, Air force specialized Hospital -National Hepatology and Tropical Research Institute (NHTMRI)	Approved 18-9-2023 Suspended 26-11-2024 (Recruitment suspension)	Compensated Chronic Liver Disease Patients	Innovative Ursoplus® capsules/ Ursofalk® capsules
73-	6/6/2023	Cipro-001	Sponsor: Minapharm, CRO:	Single center, Open Label, controlled Study to assess the safety & efficacy of Oral Cipro Diazole ®	Interventional	IV	1- General Syrgery department, Menoufia University Hospital.	Suspended 12-9-2023	Pelvi-abdominal infections and following IV antibiotics in	Innovative Cipro Diazole ® Tablets (Ciprofolxacin/ Metronidazole)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			Nagy Research	Tablets (Ciprofolxacin/ Metronidazole) versus currently used Ciprofloxacin Tablets & Metronidazole tablets in pelvi-abdominal infections and following IV antibiotics in post-operative period, for pelvi-abdominal surgeries or acute conditions					post-operative period, for pelvi-abdominal surgeries or acute conditions	
74-	15/5/2023	Sub-Thromb-001	Sponsor: Minapharm CRO: NA	A Prospective, Single- Center, Phase IV Interventional, Single Arm Trial for the Evaluation of subcutaneous recombinant Hirudin 15 mg (RB variant) in	Interventional	IV	1- Department of Orthopedics and Trauma Surgery, El-Hadra University Hospital	Withdrawn 28-8-2023	prophylaxis of Deep Vein Thrombosis (DVT) post major orthopedic operations	Innovative Thrombex (recombinant Hirudin)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				prophylaxis of Deep Vein Thrombosis (DVT) post major orthopedic operations						
75-	24/10/2023	GRC/NE-CV/EG/39/IV	Sponsor: Nerhadou Internatio- nal CRO: Genuine research center	A prospective, Multicentre, Open-label, Single-arm Interventional Study of Bisoprolol (Nerkardou) (Between Low Dose and High Dose) 5 and 10 mg ODF Treatment In Egyptian Patients with Essential Hypertension	Interventional	IV	1- Department of General Internal Medicine , Beni-Suef University Hospital 2- Department of Cardiology and vascular medicine , Fayoum University Hospital	Approved 10-3-2024 Recruiting	Essential Hypertension	Innovative Nerkardou (Bisoprolol) Oral dispersible film

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal